case
vs
testneg
control
studi
design
basi
observ
studi
influenza
vaccin
effect
case
control
recruit
time
present
acut
respiratori
ill
ari
clinic
hospit
set
individu
present
ari
test
posit
influenza
consid
case
wherea
test
neg
influenza
consid
control
studi
design
conveni
implement
inher
account
potenti
confound
due
differ
healthcareseek
behavior
vaccin
unvaccin
individu
recent
suggest
influenza
vaccin
may
increas
risk
noninfluenza
respiratori
viru
infect
decreas
temporari
nonspecif
immun
one
propos
mechan
involv
activ
innat
immun
respons
follow
influenza
infect
lead
temporari
reduct
risk
infect
differ
respiratori
viru
reduc
risk
influenza
infect
influenza
vaccin
could
paradox
creat
increas
risk
infect
noninfluenza
respiratori
virus
phenomenon
occur
could
lead
bias
estim
influenza
vaccin
effect
studi
use
laboratoryconfirm
influenza
case
influenzaneg
control
scenario
risk
noninfluenza
viral
ill
would
higher
vaccin
unvaccin
individu
influenzaneg
control
group
would
therefor
higher
proport
vaccin
individu
compar
sourc
popul
could
theoret
contribut
overestim
true
ie
bia
away
null
therefor
key
assumpt
testneg
control
design
influenza
vaccin
effect
studi
proport
noninfluenza
viral
ill
differ
influenza
vaccin
statu
goal
studi
determin
influenza
vaccin
associ
detect
noninfluenza
respiratori
virus
determin
vaccin
effect
estim
differ
differ
control
group
use
analysi
achiev
goal
analyz
avail
data
member
commun
cohort
saw
physician
acut
respiratori
ill
consent
particip
studi
influenza
vaccin
effect
influenza
season
vaccin
effect
studi
enrol
individu
age
variat
season
analysi
restrict
children
year
old
adult
year
old
particip
age
group
multiplex
revers
transcript
polymeras
chain
reaction
rtpcr
test
subsequ
perform
detect
respiratori
virus
provid
opportun
investig
relationship
influenza
vaccin
infect
viral
pathogen
young
children
older
adult
among
vulner
individu
influenza
infect
complic
calcul
influenza
vaccin
effect
group
therefor
high
import
marshfield
clinic
research
foundat
conduct
season
studi
influenza
vaccin
effect
wisconsin
popul
cohort
sinc
season
detail
season
studi
report
elsewher
briefli
patient
ari
recruit
influenza
season
primari
care
clinic
urgent
care
emerg
depart
acut
care
hospit
symptom
elig
criteria
vari
season
includ
feverfeverish
cough
season
individu
ill
durat
day
day
exclud
minim
fals
neg
rtpcr
result
obtain
inform
consent
nasal
swab
children
year
old
nasopharyng
swab
adolesc
adult
obtain
place
viral
transport
media
influenza
test
symptom
onset
date
assess
enrol
interview
realtim
rtpcr
perform
season
identifi
influenza
case
test
complet
aliquot
sampl
viral
transport
media
frozen
studi
review
approv
marshfield
clinic
institut
review
board
season
studi
particip
parent
provid
inform
consent
influenza
test
multiplex
rtpcr
test
detect
addit
virus
subsequ
approv
irb
waiver
inform
consent
archiv
sampl
test
presenc
respiratori
viru
nucleic
acid
use
multiplex
respiratori
viru
panel
genmark
dx
esensor
respiratori
viral
panel
multiplex
panel
test
respiratori
syncyti
viru
rsv
b
human
rhinoviru
human
metapneumoviru
parainfluenza
virus
influenza
b
includ
subtyp
influenza
coronavirus
adenovirus
b
e
nucleic
acid
extract
swab
use
roch
magnapur
system
amplifi
use
rtpcr
targetspecif
primer
targetspecif
signal
determin
voltammetri
process
gener
electr
signal
ferrocenelabel
signal
probe
multiplex
assay
valid
influenza
rsv
b
singleplex
assay
approv
center
diseas
control
prevent
cdc
found
sensit
specif
influenza
influenza
b
rsv
respect
unpublish
data
case
defin
laboratoryconfirm
influenza
base
posit
realtim
rtpcr
test
influenza
type
b
three
differ
control
group
construct
analyt
purpos
control
group
includ
individu
test
neg
influenza
influenzaneg
control
group
includ
individu
neg
influenza
posit
least
one
respiratori
viru
multiplex
panel
virusposit
control
group
includ
individu
neg
respiratori
virus
multiplex
panel
panneg
control
first
control
group
standard
definit
use
testneg
casecontrol
design
wherea
second
third
control
group
repres
subset
first
group
vaccin
statu
date
determin
realtim
internetbas
registri
use
immun
provid
serv
local
popul
wwwrecinorg
case
control
consid
vaccin
season
trival
inactiv
influenza
vaccin
tiv
live
attenu
influenza
vaccin
laiv
receiv
least
day
ari
symptom
onset
children
partial
vaccin
accord
advisori
committe
immun
practic
acip
definit
ie
receiv
recommend
dose
exclud
separ
analys
conduct
children
year
old
adult
year
old
first
enrol
includ
individu
given
season
vaccin
statu
compar
virusposit
control
panneg
control
use
logist
regress
odd
ratio
describ
associ
vaccin
influenza
infect
determin
separ
casecontrol
group
logist
regress
logist
regress
model
includ
influenza
statu
outcom
vaccin
statu
primari
exposur
variabl
adjust
potenti
confound
includ
gender
influenza
season
age
continu
presenc
chronic
diseas
confer
increas
risk
influenza
complic
interv
day
symptom
onset
swab
collect
sa
sa
institut
cari
nc
use
statist
analys
influenza
season
children
adult
contribut
uniqu
observ
respect
influenza
detect
children
adult
among
without
influenza
respiratori
viru
detect
children
adult
children
without
influenza
commonli
detect
singl
virus
rsv
n
human
rhinoviru
n
human
metapneumoviru
n
parainfluenza
n
swab
children
posit
noninfluenza
respiratori
virus
children
common
coinfect
rsv
rhinoviru
n
adult
without
influenza
commonli
detect
singl
virus
rsv
n
human
rhinoviru
n
human
metapneumoviru
n
coronaviru
n
swab
adult
posit
noninfluenza
respiratori
virus
adult
common
coinfect
rsv
coronaviru
n
virusposit
controlgroup
pannegativecontrolgroup
differ
regard
age
gender
vaccin
statu
interv
symptom
onset
swab
either
children
adult
tabl
proport
children
highrisk
health
condit
differ
control
group
adult
highrisk
health
condit
panneg
control
group
virusposit
control
group
tabl
univari
analys
associ
found
influenza
vaccin
singl
viru
detect
rsv
adenoviru
human
metapneumoviru
human
rhinoviru
coronaviru
singl
infect
parainfluenza
viru
less
common
vaccin
children
vaccin
children
p
among
adult
signific
associ
opposit
direct
parainfluenza
detect
vaccin
unvaccin
adult
p
children
adult
adjust
odd
influenza
infect
significantli
lower
vaccin
group
rel
control
group
indic
signific
vaccin
effect
tabl
among
adult
adjust
odd
ratio
aor
rang
among
children
aor
rang
depend
control
group
use
children
adult
aor
use
influenzaneg
control
ie
current
standard
studi
vari
compar
aor
use
virusposit
control
aor
confid
interv
overlap
adjust
odd
vaccin
differ
significantli
panneg
control
group
vs
virusposit
control
group
either
children
p
adult
p
result
similar
analysi
repeat
exclud
children
receiv
laiv
adult
analysi
receiv
laiv
detect
noninfluenza
respiratori
viru
multiplex
rtpcr
associ
influenza
vaccin
statu
period
six
influenza
season
children
adult
virusposit
control
group
panneg
control
group
similar
term
age
distribut
gender
influenza
vaccin
statu
associ
influenza
vaccin
detect
rsv
adenoviru
human
metapneumoviru
human
rhinoviru
coronaviru
parainfluenza
infect
significantli
associ
influenza
vaccin
associ
opposit
direct
children
adult
p
valu
adjust
multipl
comparison
inconsist
children
adult
suggest
associ
result
type
error
assess
potenti
impact
noninfluenza
respiratori
virus
vaccin
effect
studi
calcul
aor
influenza
vaccin
case
control
use
differ
control
group
among
children
aor
respect
use
influenzaneg
control
virusposit
control
correspond
absolut
differ
vaccin
effect
estim
broadli
overlap
confid
interv
nearli
vaccin
children
analysi
receiv
tiv
result
similar
laiv
recipi
exclud
among
adult
year
old
adjust
odd
ratio
nearli
ident
respect
use
influenzaneg
control
virusposit
control
overlap
confid
interv
studi
found
evid
associ
influenza
vaccin
infect
noninfluenza
respiratori
viru
studi
influenza
vaccin
effect
australian
children
month
old
found
influenza
vaccin
associ
detect
respiratori
virus
nasal
swab
children
test
rtpcr
influenza
rhinovirus
rsv
parainfluenza
viru
human
metapneumoviru
enterovirus
adjust
vaccin
effect
ci
use
influenzaneg
control
ci
use
virusposit
control
author
note
higher
point
estim
vaccin
effect
use
virusposit
control
although
substanti
overlap
confid
interv
point
estim
author
specul
differ
point
estim
could
due
fals
neg
rtpcr
test
children
ie
panneg
control
due
inadequ
sampl
collect
also
mention
possibl
influenza
vaccin
could
increas
risk
infect
virus
view
biolog
implaus
relationship
influenza
vaccin
infect
noninfluenza
virus
also
investig
clinic
trial
tiv
children
studi
tiv
recipi
n
increas
risk
infect
noninfluenza
respiratori
virus
compar
placebo
recipi
n
incid
season
influenza
differ
significantli
tiv
placebo
group
author
acknowledg
associ
noninfluenza
virus
could
spuriou
suggest
receipt
tiv
could
increas
influenza
immun
expens
reduc
immun
noninfluenza
respiratori
virus
unknown
biolog
mechan
identifi
temporari
nonspecif
immun
possibl
explan
observ
accord
propos
mechan
unvaccin
children
like
acquir
influenza
infect
abbrevi
aor
adjust
odd
ratio
ci
confid
interv
uor
unadjust
odd
ratio
model
adjust
gender
influenza
season
age
year
presenc
highrisk
health
condit
interv
day
symptom
onset
swab
collect
result
innat
immun
respons
provid
temporari
nonspecif
protect
infect
respiratori
virus
describ
letter
rais
concern
bia
studi
vaccin
effect
use
rtpcr
confirm
case
influenzaneg
control
studi
rel
small
sampl
size
limit
singl
influenza
season
howev
one
studi
random
placebocontrol
trial
studi
design
less
suscept
bia
confound
compar
observ
studi
unabl
replic
previous
report
associ
children
adult
larger
sampl
size
multipl
influenza
season
howev
rule
possibl
vaccin
may
alter
suscept
noninfluenza
virus
circumst
limit
biolog
evid
support
effect
nonspecif
immun
across
viru
famili
speci
limit
evid
support
role
vaccin
immun
crossreact
tcell
respons
describ
differ
subtyp
influenza
although
crossreact
gener
innat
immun
system
like
last
day
may
appli
interact
virus
differ
famili
speci
research
also
suggest
outbreak
differ
respiratori
virus
may
interact
interfer
popul
level
mechan
may
help
explain
effect
seen
analysi
report
elsewher
conclus
find
support
hypothesi
influenza
vaccin
associ
increas
risk
infect
noninfluenza
respiratori
viru
research
may
aid
determin
biolog
plausibl
temporari
nonspecif
immun
gener
infect
specif
respiratori
virus
final
found
differ
vaccin
effect
estim
use
testneg
vs
virusposit
control
group
result
analysi
strongli
support
valid
case
vs
testneg
control
studi
design
current
use
multipl
countri
estim
influenza
vaccin
effect
outpati
set
